TABLE 2.
Differences between experts and non-experts in HS knowledge, experience, and frequency of use of HS medical and surgical treatments
| VARIABLE | KNOWLEDGE AND EXPERIENCE | FREQUENCY OF USE | ||
|---|---|---|---|---|
| EXPERT (N=49) MEAN | NON-EXPERT (N=39) MEAN | EXPERT (N=49) MEAN | NON-EXPERT (N=39) MEAN | |
| Medical treatments | ||||
| Topical clindamycin | 4.82 | 4.68 | 4.32 | 4.48 |
| Resorcinol 15% cream | 3.03 | 1.97* | 1.62 | 1.13* |
| Antibacterial washes (i.e., chlorhexidine wash) | 4.69 | 4.67 | 4.11 | 4.39 |
| Benzoyl peroxide wash | 4.62 | 4.71 | 3.97 | 4.26 |
| Oral tetracyclines | 4.77 | 4.87 | 4.39 | 4.52 |
| Oral contraceptives | 4.26 | 3.84 | 3.66 | 3.03* |
| Spironolactone | 4.74 | 4.61 | 4.42 | 3.55* |
| Combination clindamycin and rifampin therapy | 4.49 | 3.66* | 3.92 | 2.77* |
| IV Ertapenem | 3.41 | 1.74** | 2.16 | 1.29* |
| Isotretinoin | 4.51 | 3.87* | 2.53 | 2.39 |
| Acitretin | 4.54 | 3.55* | 2.71 | 1.97* |
| Methotrexate | 4.23 | 3.43* | 2.21 | 1.58* |
| Cyclosporine | 4.18 | 3.10** | 1.95 | 1.58 |
| Dapsone | 4.26 | 3.23** | 2.45 | 1.65* |
| Oral steroids | 4.54 | 3.87* | 3.00 | 2.13* |
| Adalimumab | 4.77 | 4.07* | 4.55 | 3.65* |
| Infliximab | 4.63 | 3.32** | 4.24 | 2.65* |
| Other biologics (i.e., anakinra, ustekinumab) | 4.36 | 3.19** | 3.34 | 2.13* |
| Surgical treatments | ||||
| Intralesional steroid injection | 4.72 | 4.77 | 4.36 | 4.32 |
| Local excision | 4.42 | 3.68* | 3.38 | 2.53* |
| Wide excision | 3.63 | 2.93* | 2.97 | 2.13* |
| Unroofing/deroofing | 4.05 | 3.10* | 3.38 | 2.33* |
| Laser evaporation | 2.05 | 1.87 | 1.31 | 1.19 |
| CO2 laser excision | 2.13 | 1.77 | 1.49 | 1.29 |
| Electrosurgical peeling | 1.95 | 1.65 | 1.18 | 1.13 |
| Cryosurgery | 2.36 | 2.73 | 1.33 | 1.35 |
| Incision and drainage | 4.38 | 4.23 | 3.18 | 3.19 |
| Laser hair removal | 3.49 | 2.77* | 2.87 | 2.33 |
Statistical significance of Mann-Whitney U test denoted by
*p<0.05,
**p<0.00063 (Bonferroni-adjusted α)